AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01001559 — intervention group
Intervention type: DRUG
Intervention: Serotonin and norepinephrine reuptake inhibitor (SNRI)
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
Study NCT00611429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling sessions
Description: The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
Study NCT00611429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling sessions
Description: The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
Study NCT00611429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group workshop
Description: During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
Study NCT00611429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group workshop
Description: During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
Study NCT00795704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg #2 capsules by mouth three times daily
Study NCT00773162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
Study NCT00773162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill to match seroquel
Study NCT00286585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational anesthetic
Description: Sevoflurane, dosage according to the physician in charge
Study NCT00286585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anesthetic, propofol
Description: Propofol, dosage according to the physician in charge
Study NCT03469063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AferBio
Description: Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
Study NCT03469063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AferBio
Description: Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
Study NCT00187863 — intervention group
Intervention type: BEHAVIORAL
Intervention: pain perception
Description: pain perception
Study NCT01486966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
Study NCT01486966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
Study NCT01486966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
Study NCT01486966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human soluble insulin
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
Study NCT01486966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
Study NCT01486966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
Study NCT02532517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System
Study NCT00622037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-400 based artificial tear
Description: Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
Study NCT00622037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
Study NCT02221869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem
Study NCT02221869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xyrem
Study NCT04965324 — intervention group
Intervention type: OTHER
Intervention: Anaesthesia Depth
Study NCT02354235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Study NCT02354235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teneligliptin
Study NCT02354235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Study NCT02354235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03189537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
Description: Broad-spectrum antiviral agent
Study NCT03189537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule to match Ingavirin capsule
Study NCT03522792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotensin
Description: Intravenous infusion of neurotensin
Study NCT03522792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of saline
Study NCT03522792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum meal
Description: Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
Study NCT03522792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
Study NCT01618604 — intervention group
Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing
Description: following the standardized protocol of DFNS
Study NCT01618604 — intervention group
Intervention type: PROCEDURE
Intervention: Conditioned Pain Modulation
Description: test stimulus by hot thermode conditioned stimulus by cold water bath
Study NCT05887921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Lymphadenectomy
Description: arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
Study NCT04049487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will participate in group exercise as previously described
Study NCT04049487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both groups will participate in group exercise as previously described
Study NCT01827150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Redbull, energy drink
Description: A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
Study NCT02668497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT04044469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immunization-enhancement
Description: This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
Study NCT04044469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immunization-inhibition
Description: This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
Study NCT04044469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: This group receives no further information after watching the videotaped doctor's report.
Study NCT01372059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RGRM
Description: RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
Study NCT01372059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic riding
Description: The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
Study NCT01372059 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Receives no intervention
Description: Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
Study NCT01618604 — intervention group
Intervention type: PROCEDURE
Intervention: Repetition of four QST parameters
Description: * warm detection threshold (WDT)~* cold detection threshold (CDT)~* mechanical detection threshold (MDT)~* mechanical pain threshold (MPT)
Study NCT01920854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: soluble ferric pyrophosphate
Study NCT01260714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT01260714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01260714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01260714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT03947710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein meals
Description: Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
Study NCT03947710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low- protein meals
Description: Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
Study NCT03947710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No meals
Description: Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
Study NCT02928315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
Study NCT02928315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
Study NCT04683835 — intervention group
Intervention type: DEVICE
Intervention: Neurosteer Aurora system
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
Study NCT02407223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Placebo
Description: Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
Study NCT01920854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01775150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: Health education via text messaging
Study NCT01304433 — intervention group
Intervention type: DRUG
Intervention: Venofundin 6% / Tetraspan 6%
Description: Venofundin 6% / Tetraspan 6%
Study NCT00939666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wait&see or TEM with intensive follow-up
Description: Wait\&see or TEM with intensive follow-up
Study NCT01666964 — intervention group
Intervention type: OTHER
Intervention: Blast Traumatic Brain Injury
Description: Exposure during combat to blast-wave mediated Traumatic Brain Injury
Study NCT02231801 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mother-Infant Dyad
Description: Skin-to-skin holding of preterm infants by their mothers
Study NCT02407223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Ustekinumab 45 mg
Description: Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
Study NCT02407223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: Ustekinumab 90 mg
Description: Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
Study NCT02602535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
Study NCT02602535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study NCT00803751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope
Description: will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
Study NCT00803751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Intubation using the traditional Macintosh laryngoscope
Study NCT02463110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
Study NCT02463110 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No treatment
Study NCT04019899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: * 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation.
Study NCT04019899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: study group
Description: * 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.
Study NCT02507323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: A platelet aggregation inhibitor
Study NCT02507323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: a thienopyridine class inhibitor of platelet activation and aggregation
Study NCT02507323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00597402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
Study NCT00597402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
Study NCT00597402 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (XRT)
Description: Treatment with standard XRT (radiation) for 6.5 weeks.
Study NCT00597402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
Study NCT05342558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol 100/25 mcgs
Description: Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
Study NCT05342558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umeclidinium/Vilanterol 62.5/25 mcgs
Description: Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
Study NCT05113511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510
Description: Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
Study NCT05113511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.